Saxenda
Liraglutide · 3 mg/day
Novo Nordisk
GLP-1 receptor agonist — daily dosing, shorter half-life than semaglutide.
FDA Approved
December 2014
Last Updated
March 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Medically reviewed by Dr. Sarah Mitchell, MD (Board-Certified Obesity Medicine) · Editorial Policy
How Saxenda Works
GLP-1 receptor agonist — daily dosing, shorter half-life than semaglutide.
Key Pharmacological Actions
- • Appetite suppression via GLP-1 receptors in the hypothalamus and brainstem
- • Delayed gastric emptying, extending the feeling of fullness after meals
- • Reduced "food noise" — the constant preoccupation with food
- • Improved insulin sensitivity independent of weight loss
- • Glucose-dependent insulin secretion, reducing hypoglycemia risk
Dosing & Administration
Titration Guidance
Saxenda uses a gradual dose escalation schedule over 5 weeks to full dose. Starting at 0.6 mg/day allows your body to adjust and minimizes GI side effects. Do not skip doses or increase faster than your physician recommends — this increases the risk of nausea, vomiting, and diarrhea. If side effects are severe at any dose, your doctor may extend the time at that dose before increasing.
Clinical Trial Results
SCALE Obesity
20158.4% mean weight loss at 56 weeks vs 2.8% placebo
Average Weight Loss: In clinical trials, patients taking Saxenda lost an average of 8–9% of their body weight. Individual results vary significantly — some patients lose considerably more or less than the average. Response depends on factors including baseline weight, diet, exercise, dose tolerated, and individual biology.
Side Effects
The most common side effects of Saxenda are gastrointestinal. They typically peak during dose escalation and improve over time as your body adjusts.
Contraindications
- • Personal/family history of MTC
- • MEN2 syndrome
- • Pregnancy
This is not a complete list of side effects. Serious but rare side effects include pancreatitis, gallbladder disease, and allergic reactions. If you experience severe abdominal pain, signs of allergic reaction, or any concerning symptoms, contact your healthcare provider immediately. Consult the full FDA prescribing information for a comprehensive list.
Cost & Insurance Coverage
Coverage Information
- • Commercial Insurance: Many plans cover Saxenda with prior authorization. Requirements typically include documentation of BMI ≥30 (or ≥27 with comorbidity) and, in some cases, documented failure of lifestyle modification.
- • Medicare Part D: Coverage is expanding. Coverage varies by plan and is improving in many states.
- • Manufacturer Savings: Novo Nordisk offers savings cards that can significantly reduce out-of-pocket costs for eligible commercially insured patients.
Eligibility Criteria
Pros & Cons
Advantages
- ✓Longest-approved GLP-1 for obesity (since 2014)
- ✓Extensive real-world safety data
- ✓FDA-approved for obesity
- ✓Approved for children 12+ (2020)
Limitations
- ✗Daily injection vs weekly for newer agents
- ✗Lower weight loss efficacy than semaglutide/tirzepatide
- ✗High frequency of injection site reactions
- ✗High cost for older drug
Frequently Asked Questions
Quick Facts
Saxenda — From Our Blog
Medically reviewed articles to help you understand Saxenda (Liraglutide).
Liraglutide (Victoza/Saxenda): The Original GLP-1 That Still Has a Role in 2026
Liraglutide was the first GLP-1 for weight loss. With newer options available, does it still make sense? Here's an honest assessment.
GLP-1 Alternatives for Weight Loss: Evidence-Based Options if You Can't Access These Drugs
If GLP-1 medications aren't accessible — due to cost, shortages, medical contraindications, or insurance — these evidence-based alternatives can still produce meaningful weight loss. We compare every option from FDA-approved drugs to structured lifestyle interventions.
What Happens When You Stop Taking GLP-1 Medications?
Studies show most patients regain significant weight after stopping GLP-1 drugs — often two-thirds of what they lost within one year. Understand the rebound biology, timeline, and evidence-based strategies to minimize weight regain.
Medical Disclaimer
This page provides general information about this medication for educational purposes only. It does not constitute medical advice and should not be used as a substitute for consultation with your healthcare provider. Always consult your physician or pharmacist before starting, changing, or stopping any medication. Drug pricing, insurance coverage, and clinical data may change after publication.